Demand for primary care services is expected to grow. The Medicare program is anticipating an increase from 54 million beneficiaries today to over 80 million beneficiaries in 2030, many of whom will have longer life expectancies, high rates of obesity, and chronic conditions. 1 These population changes will challenge a volatile primary care workforce facing major compositional changes in order to meet projected health care
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Yet, despite an established body of evidence that NP and physician management of patients yield similar outcomes, [5] [6] [7] [8] [9] [10] many states continue to have restrictive SoP, especially for NP prescribing. Legally, NP prescribing is regulated in a separate statue from NP practice. A state allowing NPs to diagnose and manage patients without physician supervision may require oversight of a physician for NP prescribing. A large part of the ongoing concern of expanding SoP regulations may stem from the limited knowledge of NP prescribing outcomes, a neglected consideration in studies comparing NP and PCP care that our study aimed to address.
The purpose of this paper was to add to the quality outcomes literature on NP and physician care by examining medication adherence, cost and utilization. Previous studies have not examined the combination of clinical, cost and utilization outcomes in one sample, providing insights only into a fraction of the patient's health care experience. [11] [12] [13] [14] Understanding patient outcomes across the spectrum of health care delivery and understanding the role of primary care providers in meeting desirable goals within and outside of the office-based setting are increasingly important for alternative payment models rewarding higher quality and lower institutional costs. 15 In particular, we need better information on clinical decisions that lead to more efficient care. This could be, for example, low cost efforts to improve adherence that results in less use of specialty or institutional care.
We chose medication adherence as our clinical outcome because of the lack of robust NP prescribing outcomes in prior studies. One study examined the volume, types, and dosages of medications in
Medicare beneficiaries attributed to NPs and physicians. 13 Another study used quality indicators related to disease management and appropriate medication use in survey data of patient visits. 16 Both studies reported comparable prescribing patterns of NPs and physicians.
Closest to our study in design is a study that examined the medication possession ratio (MPR) over 1 year of data in a sample of Medicare diabetes patients. 17 Rates were comparable between patients who received care from either an NP or physician. However, the MPR can lead to overestimation in adherence and is not recommended by the National Quality Forum (NQF). 18, 19 Further, research has shown a strong link between adherence, cost, and utilization for different patient populations, [20] [21] [22] [23] making it an ideal outcome for the purpose of this study. Specifically, we examined the effect of being attributed to NP or PCP care on achieving good adherence (proportion of days covered >0.8), costs (Part B and office-based costs), and utilization (emergency room visits) for three cohorts of Medicare beneficiaries.
| Medication adherence
Medication adherence is a compelling measure because it captures prescribing practices and patient behavior. Good adherence is at least partly driven by selecting tolerable and effective medications along with a patient's commitment, cost of the medication, and willingness to take the drug. Provider communication, trust, and educating the patient on the medication and its side effects are important provider factors associated with good adherence. [24] [25] [26] [27] [28] Based on the conceptual underpinnings of nursing care, NPs may be more likely assess socio economic and other factors contributing to the medication adherence, such as out-of-pocket expenses and medication preferences. We postulated that NPs spend more time assessing these factors. Thus, we hypothesized that beneficiaries attributed to NPs are more likely to achieve good adherence than physician-attributed beneficiaries.
| ME THODS

| Sample
The sample was designed to be representative of NPs and PCPs treating Medicare beneficiaries in 2009-2010. This was done in several steps starting with a random sample of NPs (specialty code "50" = nurse practitioner) and PCPs (specialty code "08" = family medicine and "11" = internal medicine) from the universe of clinicians with independent billing numbers (NPIs) in 2009/2010. This resulted in 4,065 NPs and 549 PCPs.
As a second step, for each provider, we gathered all beneficiaries they treated and all their claims at a ratio of 4 NP beneficiaries to 1 physician beneficiary until we reached a maximum sample of 1 million beneficiaries. Since Medicare beneficiaries see many providers, this second step resulted in capturing many more NPs and PCPs than in the original random sample (NPs = 51 595; PCPs = 160 000). It also resulted in many specialist clinicians, which we excluded from the analysis.
We selected beneficiaries who were 65 years of age or older at baseline; were continuously enrolled in Part A, B, and D; did not switch Part D plans in any calendar year; had two or more prescription claims in at least one of the drug classes studied; and had no missing observations for all independent variables. Figure 1 illustrates the sample selection process after attribution. The sample eligible for attribution to a primary care provider consisted of 475 291 beneficiaries. To better understand the effect of provider type on patient outcomes over time, the sample was extended to multiple years, creating a longitudinal cohort.
| Data
The primary analysis used two core data files: Part D prescription drug event (PDE) claims to evaluate medication adherence and the beneficiary comorbidity information and Part B claims for provider attribution (described below). Table S1 shows a list of the Medicare data files used in each study year.
| Attribution
Because beneficiaries received care from many different clinicians during a year, a primary care provider type (NP or PCP) needed to MUENCH Et al.
be for each beneficiary to test the effect of the type of provider on study outcomes. We followed a validated attribution method described in more detail elsewhere (Perloff et al 2015) . This method assigns beneficiaries to either an NP or PCP based on the provider type who (a) provided the highest proportion of evaluation and management (E&M) paid amounts to that beneficiary in 2009 and (b) provided at least 30% of the overall paid services. In the rare case of a tie (<500), the provider type was chosen at random.
This analysis excluded beneficiaries who could not be assigned to a dominant provider, for example when no one NPI accounted for 30% of E&M services. Worth noting, incident-to billing may mean that some beneficiaries with a high volume of NP care could have been assigned to physicians. This may happen when care by an NP is billed under the physician's NPI. This miss-attribution would lead to less notable differences between the two provider groups.
| Dependent variables
The empirical analysis included medication adherence and measures of health services cost and use, the first was calculated from the PDE data, the latter two were obtained from the Cost and Use segment of the beneficiary summary file. 
| Medication adherence
Medication adherence was measured using the proportion of days covered (PDC) method. The PDC is calculated as the number of days in the measurement period covered by medications in a therapeutic class divided by number of days in the measurement period. For example, for a February 1st start date and a 300-day supply in the same year, the medication adherence rate is 0.9 or 90% (300 divided by 333). The National Quality Forum (NQF) endorsed using PDC for medication adherence and defined high adherence as a PDC of at least 80%. 29 We used NQF medication adherence quality measure
0541-Proportion of Days Covered (PDC): 3 Rates by Therapeutic
Category. 29 
| Costs: general evaluation and management and primacy care management expenditures
Our cost outcomes were the beneficiaries' general evaluation and management (GE&M) paid amounts, and their primary care evaluation and management paid amounts (PCE&M). Both were treated as actual dollar amounts and were inflation adjusted with 2013 as the base year. Specifically, GE&M costs capture services for the management of a patient in the ER, hospital, nursing home, or specialty care context (M3, M4, M5, and M6). PCE&M, on the other hand, focuses on services provided in an office setting for new or established patients. 30 These measures include all services with a BETOS code of "M1A" or "M1B."
To determine these costs, The Centers for Medicaid and Medicare Services (CMS) sums all claims with the relevant procedure code for the beneficiary for the year. The total includes NP services, reimbursed at 85% of the physician rate, and physician services. Because there is no price standardization, we include adjusters for geography in multivariate models to capture variation in reimbursement rates by region.
| Use: emergency department visits
Our utilization outcome was a binary variable measuring whether a beneficiary had any inpatient emergency department (ED) visits, a utilization measure extensively used in the literature, particularly in conjunction with medication adherence. 31, 32 TA B L E 1 (Continued)
segment. It does not measure whether the visit resulted in an inpatient admission. During our study period, 5 states implemented independent SoP for NPs.
| Independent variables
For ER visit and cost analyses, we also included medication adherence as a control variable to capture the relationship between good adherence and positive cost and utilization outcomes.
| Analysis
| Propensity score-weighted analysis
Because the choice of primary care provider (NP vs PCP) can be considered voluntary, beneficiaries assigned to NPs might differ from those assigned to PCPs on characteristics such as health status or preference to see a local provider. To adjust for selection bias due to the observable differences between the two groups, we employed propensity score (PS)-weighting to balance the characteristics between NP and PCP beneficiaries for each drug class cohorts.
Specifically, we conducted a logistic regression model for choosing an NP as a primary care provider in 2009 and derived the PS of being assigned to the NP group in that year by adjusting for the following study covariates: all available demographics (age, gender, race, dual eligible, and urban versus rural residence), CMS region, Elixhauser comorbidities, and plan characteristics (type of health plan and plan generosity). We then weighted each beneficiary using inverse probability of treatment weighting to adjust for differences between patients assigned to NPs and PCPs. Specifically, the weights are
where T i is an indicator denoting whether or not the ith beneficiary was assigned to NPs; s i denotes her PS of being assigned to the NP group. 39 We carried weights forward and applied them to all 4 years of data. The advantage of PS-weighting compared to matching is that since there are substantially more beneficiaries assigned to PCPs than NPs, PS-weighting allows us to use all the individuals in the sample rather than matched cases only. 40 We checked the balance of covariates between treated and untreated group for all three cohorts before and after weighting (Table 1 ) and also checked the overlap assumption ( Figure S1 ).
| Regression analyses
Our regression estimations had three parts: (a) evaluation of good medication adherence, (b) evaluation of office-based and non-office-based costs, and (c) evaluation of inpatient ER visits.
The impact of the type of primary care provider on whether a patient had good adherence (PDC ≥ 80%) was estimated using logistic regression since the dependent variable was dichotomous. The probability of having an inpatient ER visit was also estimated using logistic regression. To model the skewed health care costs in our data, we extended the generalized linear model (GLM) to our longitudinal data by fitting a population-averaged model using generalized estimating equations (GEE), with a link function suggested by a Park test. 41 All models included control variables discussed above. Analyses were performed using Stata 14.0 (StataCorp LP, College Station, TX, USA), and we used statistical significance levels at conventional levels.
| RE SULTS
Our sample consisted of 475 291 assigned beneficiaries, of whom 19% were assigned to NPs (N = 88 017) and 81% were assigned to Beneficiaries assigned to NPs were significantly more likely to be non-white, younger, female, dual eligible for Medicare and Medicaid, and living in rural areas. They were also significantly less likely to have each of the Elixhauser comorbid conditions, with the exception of paralysis, neurological disorders, AIDS, alcohol abuse, drug abuse, and psychoses.
This pattern was consistent across the three drug groups. Applying the PS weights balanced the two groups of beneficiaries in all three-drug cohorts on all demographic and diagnostic characteristics (Table 1) .
A crucial assumption that underlies PS analyses is sufficient overlap between treatment and control group in the distribution of covariates.
To check whether the overlap assumption was met, we plotted the distribution of the PS for those assigned to the NP group (ie, being treated) or the PCP group ( Figure S1 ). The two PS distributions achieved a high degree of overlap for each drug group, suggesting PS-weighting analysis significantly mitigated the selection bias by equating groups based on the covariates in our sample. All analyses were restricted to the drug cohort specific regions of common support. Table 2 shows the percent of beneficiaries who had good adherence (PDC >80%) under NP and physician provided care in each of the three drug classes. There was no difference between the share of NP and PCP attributed beneficiaries who had good adherence in two of the drug groups. In the statin group, a slightly larger fraction of PCP attributed beneficiaries had good adherence (NP 76.5% vs PCP 77.3%; P < 0.05). Table 3 reports the effect of the type of provider on good adherence (PDC >80%) using the PS-weighted multivariable logistic
| Medication adherence
analysis. There were no differences in the probability of achieving good adherence between NP and PCP attributed beneficiaries in two of the drug classes studied. In the cohort of beneficiaries taking statins, the probability of having good adherence was 1 percentage point lower in the group of beneficiaries attributed to NPs (P < 0.05). Table 3 , reporting probabilities. After adjusting for demographic characteristics, geography, comorbidities, and SoP the propensity to see an NP, and medication adherence, NP beneficiaries were significantly less likely to have an ER visit across all cohorts, with an effect size difference between NP and PCP attributed beneficiaries ranging between 2.6% to 3.1% depending on the cohort (Statin cohort 2.6% (P < 0.01), RASA cohort 2.9% (P < 0.01), diabetes cohort 3.1%
| Hospital emergency department visit
(P < 0.01)).
| Costs
In unadjusted results, NP attributed beneficiaries in all three drug groups had significantly lower costs. For non-office-based costs, differences between NP and PCP beneficiaries were the largest in the RASA group and the smallest in the statin group.
The same pattern emerged for office-based costs. Table 2 shows the unadjusted differences between NP and PCP attributed beneficiaries for each drug cohort. In multivariate modeling, NP at- Table 3 ).
As expected, good adherence played an important role in all cost and use models across all drug cohorts and was associated with significantly lower costs and lower ER use (Table 2 ). Detailed regression results for all models are available upon request.
| Robustness analyses
We conducted several robustness analyses to address potential concerns related to attribution, missing data, gaps in medication adherence, and SoP. Because attribution to the primary care provider was carried out using 2009 data, it is possible that a beneficiary may receive the majority of his/her care from a different type of provider in the follow-up years. To test the stability of attribution, we compared assignments using 2 years of data to assignments using only a single year. We found that 70% of beneficiaries were assigned to the same provider using the 2-year method compared to the 1-year method.
This suggests that although some beneficiary-provider relationships To ensure that our analysis was robust to potential differences in beneficiaries who experienced medication gaps, we excluded beneficiaries with gap years. Depending on the drug class, between 9%-25% of our sample experienced a single gap year, and only 2%-5% Furthermore, we conducted a follow-up analysis on a subset of beneficiaries with conditions that are considered ambulatory care sensitive conditions (ACSC). Using chronic condition indicators, we were able to identify six out of ten chronic ACSC, including hypertension, congestive heart failure, chronic obstructive pulmonary disease, anemia, diabetes, and asthma. Subsetting the sample to beneficiaries with ACSCs identified beneficiaries in whom the effect of the primary care provider may be more pronounced. This was reflected in the coefficients, which indicated slightly larger effect sizes on the cost and use measures, supporting that our results are driven by differences in primary care provider type and are not due to unobserved factors systematically affecting beneficiaries with non-ACSCs.
Finally, because SoP regulations can have a substantial effect on NP (and physician) practice, we estimated models only for those beneficiaries who resided in states in which NPs could practice without physician oversight. Results were directionally and qualitatively similar; however, ER visits and office-based costs had smaller effect sizes for NP assignment. Potential explanations could be the unexplained geographic variations in costs and utilization, or that the effect of NP care, while remaining robust, might be more modest for the outcomes of ER visits and Part B costs than suggested in Table 3 .
Results are available in Table S2 . All other robustness analyses are available upon request. Notes: All models adjusted for beneficiaries' sex, race, age, dual eligibility status, provider type, rural region, CMS regions, year, NP independence, and Elixhauser comorbidities.
| D ISCUSS I ON
Cost and utilization models also adjusted for high adherence. Coefficients for binary outcomes are reported in probabilities.
Results based on an attribution threshold of 30%. Standard errors in parentheses; *P < 0.10, **P < 0.05, ***P < 0.01. Propensity score ranges: anti-diabetics: ≥0.0296622 and ≤0.5590561; RASA: ≥0.0274983 and ≤0.5630087; statins: ≥0.0322372 and ≤0.5937169.
educating patients in medication use, and follow-up. It is not surprising that adherence reduces the expenditures for inpatient and specialist services. This suggests that consistent use of chronic medications may off-set the need for some visits or services. In contrast, the impact of adherence is much lower when it comes to office-based care. There is no added effect of having both good adherence and a particular provider type, suggesting that adherence is not the driver of PCP differences.
Overall, our findings on good medication adherence suggest that the pharmaceutical treatment of beneficiaries attributed to 
